MT 1988
Alternative Names: MT-1988Latest Information Update: 29 Dec 2022
At a glance
- Originator Monument Therapeutics
- Developer Monument Therapeutics; University of Nottingham
- Class Antipsychotics; Behavioural disorder therapies
- Mechanism of Action Nicotinic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Schizophrenia
- Research Attention-deficit hyperactivity disorder; Autistic disorder
Most Recent Events
- 29 Dec 2022 Early research in Attention-deficit hyperactivity disorder in United Kingdom (unspecified route) (Monument Therapeutics pipeline, December 2022)
- 30 Jun 2022 Early research in Autistic disorder in United Kingdom (unspecified route) in June 2022 (Monument Therapeutics pipeline, June 2022)
- 30 Jun 2022 Preclinical trials in Schizophrenia in United Kingdom (unspecified route) in June 2022 (Monument Therapeutics pipeline, June 2022)